Table 1.
Baseline characteristics by treatment group (n = 293).
| No IGRT N = 48 n (%) |
IGRT – S N = 137 n (%) |
IGRT – R N = 108 n (%) |
|
|---|---|---|---|
| Randomisation option | |||
| No IGRT v IGRT-S v IGRT-R | 16 (33) | 13 (9) | 13 (12) |
| No IGRT v IGRT-S | 32 (67) | 32 (23) | – |
| IGRT-S v IGRT-R | – | 92 (67) | 95 (88) |
| Age (years) | |||
| Median (IQR) | 71 (66–73) | 72 (66–75) | 71 (67–75) |
| Range | 57–80 | 53–82 | 54–80 |
| Time from histological confirmation of prostate cancer to randomisation (wks) | |||
| Median (IQR) | 16 (13–25) | 17 (13–27) | 18 (13–25) |
| Range | 6–350 | 3–278 | 4–265 |
| T stage (clinical assessment) | |||
| T1 | 16 (33) | 46 (34) | 43 (40) |
| T2 | 27 (56) | 83 (61) | 56 (52) |
| T3 | 5 (10) | 8 (6) | 9 (8) |
| Grading group(Gleason score) | |||
| 1 (3 + 3) | 13 (27) | 42 (31) | 31 (29) |
| 2 (3 + 4) | 30 (63) | 61 (45) | 55 (51) |
| 3 (4 + 3) | 4 (8) | 32 (23) | 19 (18) |
| 4 (4 + 4, 3 + 5, 5 + 3) | 1 (2) | 2 (1) | 3 (3) |
| PSA (pre-hormone treatment) (ng/ml) | |||
| Median (IQR) | 9.5 (6.8–15.2) | 9.7 (6.9–12.5) | 8.3 (6.9–11.4) |
| Mean (SD) | 11.1 (4.9) | 10.3 (4.6) | 9.1 (3.8) |
| PSA (ng/ml) | |||
| 0.0–4.99 | 2 (4) | 13 (10) | 12 (11) |
| 5.0–9.99 | 23 (48) | 57 (42) | 60 (56) |
| 10.0–19.99 | 20 (42) | 65 (48) | 36 (33) |
| 20.0–49.99 | 3 (6) | 2 (2) | 0 |
| NCCN Risk group | |||
| Low | 2 (4) | 16 (12) | 17 (16) |
| Medium | 38 (79) | 109 (80) | 80 (74) |
| High | 8 (17) | 12 (9) | 11 (10) |
| CHHiP treatment allocation | |||
| 74 Gy/37Fr | 18 (38) | 44 (32) | 33 (31) |
| 60 Gy/20Fr | 15 (31) | 48 (35) | 37 (34) |
| 57 Gy/19Fr | 15 (31) | 45 (33) | 38 (35) |